HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that its management team will participate in the following upcoming conferences: Craig-Hallum 15th Annual Alpha Select Investor Conference – November 19, 2024, New York, New York Roth 13th Annual Deer Valley Event – […]
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and
(NASDAQ:PPBT),(TASE:PPBT.TA), Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15,
(NYSE:ORN), HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that its management team will participate in the following upcoming conferences: Craig-Hallum 15th Annual Alpha Select Investor Conference – November 19, 2024, New York, New York Roth 13th Annual Deer Valley Event
(NASDAQ:OPT),(AUST:OPT.AX), Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
Definitive agreement includes the sale of U.S. wellness clinics and a partnership to launch a technology-driven clinic management solution for mental health care providers. — Executed a definitive agreement withStella for the sale of Numinus Wellness clinics for US$3.53 million — Focusing on business units and product development (“Numinus Network”) to facilitate clinic efficiency and
Old Mill Road Recording is thrilled to announce the release ofKeep Moving Forward, a new EP from Benjamin Lerner, a Vermont-based Recording Artist, Recovery Advocate, Writer, Radio Host, and Social Media Content Creator. A former IV heroin addict (sober since 6/2016), Lerner’s CLEAN campaign journals his struggles and journey in sobriety. Keep Moving Forwardis the
Company to Expand Manufacturing Operations at First Commercial Plant to Deliver Innovative Product Enhancement Options to the Food Industry Plantible Foods, a technology company unlocking the power of plants to promote the health and longevity of people and the planet, today announced the closing of a $30 million Series B funding round. The round was
— IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program — ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin’s lymphoma (NHL) — The planned clinical study will be executed as part of strategic clinical collaboration
accesso Technology Group(AIM: ACSO), the premier technology solutions provider for attractions, leisure, entertainment and cultural markets worldwide, with venues in more than 30 countries, will showcase its most innovative and comprehensive line-up of attractions technology solutions yet at IAAPA Expo Orlando from November 19-22, 2024, Booth 5131. accesso, will highlight how it leverages deep industry